SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
Nature Medicine2018Vol. 24(4), pp. 512–517
Citations Over TimeTop 1% of 2018 papers
Leila Dardaei, Hui Qin Wang, Manrose Singh, Paul Fordjour, Katherine X Shaw, Satoshi Yoda, Gráinne Kerr, Kristine Yu, Jinsheng Liang, Yichen Cao, Yan Chen, Michael S. Lawrence, Adam Langenbucher, Justin F. Gainor, Luc Friboulet, Ibiayi Dagogo‐Jack, David T. Myers, Emma Labrot, David A. Ruddy, Melissa Parks, Dana Lee, Richard H. DiCecca, Susan E. Moody, Huai-Xiang Hao, Morvarid Mohseni, Matthew J. LaMarche, Juliet Williams, Keith Hoffmaster, Giordano Caponigro, Alice T. Shaw, Aaron N. Hata, Cyril H. Benes, Fang Li, Jeffrey A. Engelman
Related Papers
- → The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models(2016)321 cited
- → Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it(2017)24 cited
- → Abstract 4795: Potency of a new ALK/ROS1 inhibitor TPX-0005 to ALK G1202R mutation and ROS1 G2032R mutation(2018)2 cited
- → Should alectinib or ceritinib be given as first line therapy for ALK positive non-small cell lung cancer patients instead of crizotinib?(2017)2 cited
- → Stepping in the right direction but still some ways to go(2019)